Milind Deshpande

Filings by Milind Deshpande span 2 companies, the busiest being Achillion Pharmaceuticals Inc and Spero Therapeutics, Inc. Over a trading history stretching from 27 May 2011 to 23 June 2026, the count stands at 30 filings.

The open-market side counts 1 purchase for €9,519 alongside 12 sales for €3.6M. On balance, insiders were net sellers of €3.6M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 5 share grants and 12 option exercises.

The record was last updated on 25 June 2026 with a share grant in Spero Therapeutics, Inc. The last insider purchase was made public on 5 December 2016, 3,625 days ago. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.